XML 28 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Marketable securities
 6 Months Ended
Jun. 30, 2024
Marketable Securities  
Marketable Securities

6. Marketable Securities

​

Available-for-sale debt securities were classified on the Condensed Consolidated Balance Sheets at fair value as follows:

​

​

​

​

​

​

​

​

​

​

June 30,

​

December 31,

​

    

2024

​

2023

Cash and cash equivalents

​

$

997

​

$

4,729

Marketable securities

​

​

98,737

​

​

71,601

Total

​

$

99,734

​

$

76,330

​

The following table summarizes the available-for-sale securities held as of June 30, 2024 and December 31, 2023:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

June 30, 2024

​

Amortized Cost

    

Gross Unrealized Gains

    

Gross Unrealized Losses

​

Fair Value

Corporate debt securities

​

$

62,603

​

$

6

​

$

(181)

​

$

62,428

U.S. Treasury securities

​

​

22,938

​

​

—

​

​

(3)

​

​

22,935

Government-sponsored securities

​

​

7,492

​

​

3

​

​

(4)

​

​

7,491

Commercial paper

​

​

6,883

​

​

—

​

​

(3)

​

​

6,880

Total

​

$

99,916

​

$

9

​

$

(191)

​

$

99,734

​

​

​

​

​

​

​

​

​

​

​

​

​

December 31, 2023

​

​

​

​

​

​

​

​

​

​

​

​

Corporate debt securities

​

$

41,610

​

$

47

​

$

(45)

​

$

41,612

U.S. Treasury securities

​

​

30,189

​

​

8

​

​

—

​

​

30,197

Government-sponsored securities

​

​

4,517

​

​

4

​

​

—

​

​

4,521

Total

​

$

76,316

​

$

59

​

$

(45)

​

$

76,330

​

The following table summarizes the contractual maturities of available-for-sale securities other than investments in money market funds as of June 30, 2024 and December 31, 2023:

​

​

​

​

​

​

​

​

​

​

June 30,

​

December 31,

​

    

2024

​

2023

Matures within one year

​

$

62,076

​

$

61,672

Matures after one year through five years

​

​

37,658

​

​

14,658

Total

​

$

99,734

​

$

76,330

​

The unrealized losses on the Company’s available-for-sale securities were immaterial as of June 30, 2024 and December 31, 2023. In addition, there were no sales of marketable securities during the three and six months ended June 30, 2024. Net unrealized holding gains or losses for the period that have been included in accumulated other comprehensive loss were not material to the Company’s Condensed Consolidated Statements of Operations.

​

The Company did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities during the three and six months ended June 30, 2024. The Company reviews its investments for other-than-temporary impairment whenever the fair value of an investment is less than amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company did not hold any securities with other-than-temporary impairment as of June 30, 2024 and December 31, 2023.